SWP
ABBV icon

Semus Wealth Partners’s AbbVie ABBV Stock Holding History

Semus Wealth Partners’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$606K Sell
2,408
-95
-4% -$20.4K 0.29% 60
2026
Q1 		$544K Buy
2,503
+3
+0.1% +$665 0.3% 59
2025
Q4 		$571K Buy
2,500
+11
+0.4% +$2.51K 0.31% 57
2025
Q3 		$576K Buy
2,489
+39
+2% +$7.94K 0.33% 52
2025
Q2 		$455K Buy
2,450
+23
+0.9% +$4.28K 0.29% 63
2025
Q1 		$508K Buy
2,427
+35
+1% +$6.8K 0.35% 51
2024
Q4 		$425K Sell
2,392
-41
-2% -$7.54K 0.28% 63
2024
Q3 		$480K Buy
2,433
+27
+1% +$5.04K 0.34% 57
2024
Q2 		$413K Buy
2,406
+231
+11% +$38.3K 0.32% 60
2024
Q1 		$396K Sell
2,175
-1
-0% -$172 0.33% 72
2023
Q4 		$337K Buy
2,176
+23
+1% +$3.35K 0.28% 79
2023
Q3 		$321K Buy
2,153
+17
+0.8% +$2.5K 0.3% 77
2023
Q2 		$288K Sell
2,136
-38
-2% -$5.57K 0.26% 86
2023
Q1 		$346K Sell
2,174
-212
-9% -$32.4K 0.37% 65
2022
Q4 		$386K Buy
+2,386
New +$366K 0.47% 59

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Semus Wealth Partners's ABBV Position: Q2 2026 in Review

Semus Wealth Partners reduced its AbbVie (ABBV) stake by 3.8% in Q2 2026, selling an estimated $20.4K and leaving 2,408 shares worth $606K. The position accounts for 0.29% of the portfolio, ranked #60.

Semus Wealth Partners first reported a position in ABBV in Q4 2022 and has held it in 15 quarters since. 4,221 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Semus Wealth Partners held 2,408 shares of AbbVie worth $606K as of Q2 2026.
  • Semus Wealth Partners sold 95 AbbVie shares in Q2 2026, an estimated $20.4K.
  • AbbVie made up 0.29% of Semus Wealth Partners's portfolio in Q2 2026, its #60 holding.
  • Semus Wealth Partners first reported a position in AbbVie in Q4 2022 and has held it in 15 quarters since.
  • 4,221 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Semus Wealth Partners's 13F filing for Q2 2026, filed 10 Aug 2026.